Tamsulone-FS--a novel Russian alpha1A/D-adrenoblocker (Farm-Syntez)--was studied in a randomized multicenter comparative trial in patients with prostatic adenoma. Pilot results agreed with other trials published in the literature and demonstrated tamsulone-FS efficacy and safety for management of lower urinary tract symptoms caused by prostatic adenoma. The efficacy and safety of tamsulone-FS was comparable to those of omnik. This drug can be recommended for wide clinical practice in prostatic adenoma. It is registered by Roszdravnadzor (certificate N LC-000859 of 03.11.2005) and allowed for production and sale.

Download full-text PDF

Source

Publication Analysis

Top Keywords

prostatic adenoma
16
patients prostatic
8
randomized multicenter
8
multicenter comparative
8
efficacy safety
8
[pilot tamsulone-fs
4
tamsulone-fs patients
4
prostatic
4
adenoma
4
adenoma randomized
4

Similar Publications

A cross-tissue transcriptome-wide association study identifies new susceptibility genes for benign prostatic hyperplasia.

Sci Rep

January 2025

Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730030, People's Republic of China.

Benign prostatic hyperplasia (BPH) is a prevalent urinary system disorder. Despite evidence of a significant genetic component from previous studies, the specific pathogenic genes and biological mechanisms are still largely unknown. The study utilized the FinnGen R10 dataset, encompassing 177,901 individuals (36,601 cases and 141,300 controls), and the GTEx v8 EQTLs files to conduct single-tissue and cross-tissue transcriptome-wide association studies (TWAS).

View Article and Find Full Text PDF

Can bladder neck thickness on magnetic resonance imaging (MRI) predict early outcomes after anatomic enucleation of the prostate (AEEP) in benign prostatic hyperplasia patients with small-volume prostate?

Clin Radiol

December 2024

Department of Urology, Urology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou, 350005, China; Department of Urology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, 350212, China; Fujian Key Laboratory of Precision Medicine for Cancer, The First Affiliated Hospital, Fujian Medical University, Fuzhou, 350005, China. Electronic address:

Aim: We aimed to evaluate whether preoperative bladder neck thickness (BNT) measured by magnetic resonance imaging (MRI) can guide surgical decisions in benign prostatic hyperplasia (BPH) and primary bladder neck obstruction (PBNO) patients with a small volume (≤30 mL).

Materials And Methods: The clinical data of 403 patients were retrospectively collected. The Kappa consistency test was used to compare subjective (IPSS-voiding) and objective (Qmax) postoperative outcomes.

View Article and Find Full Text PDF

Prostate cancer, a leading cause of cancer-related mortality among men, often presents challenges in accurate diagnosis and effective monitoring. This systematic review explores the potential of exosomal biomolecules as noninvasive biomarkers for the diagnosis, prognosis, and treatment response of prostate cancer. A thorough systematic literature search through online public databases (Medline via PubMed, Scopus, and Web of science) using structured search terms and screening using predefined eligibility criteria resulted in 137 studies that we analyzed in this systematic review.

View Article and Find Full Text PDF

Purpose: To compare outcomes of transurethral resection of the prostate (TURP) across different regions worldwide over the past two decades.

Methods: A systematic review and meta-analysis of randomized clinical trials indexed to PubMed that assessed TURP. A total of 102 studies with 8,454 patients were included and grouped by continents: Europe, Asia, Africa, and Others (North America, South America, and Australia).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!